echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Dechi Pharmaceuticals Selinexor's listing application was accepted by NMPA

    Dechi Pharmaceuticals Selinexor's listing application was accepted by NMPA

    • Last Update: 2021-01-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Deki Pharmaceuticals has recently submitted applications for the listing of selinexor for three types of hematoma adaptations, including multiple myeloma and diffuse large B-cell lymphoma.
    , five treatment options for selinexor for multiple myeloma and diffuse large B-cell lymphoma have been included in the Guidelines of the National Comprehensive Cancer Network (NCCN®).
    As the world's first approved SINE compound, selinexor can cause in-nucleus storage and activity of tumor suppressor and other growth-regulating proteins, as well as lower levels of a variety of carcinogenic proteins in the plasma, and induce apoptosis of large numbers of solid and blood tumor cells in vitro and in vivo without affecting normal cells.
    clinical studies have shown that ATG-010 has obvious efficacy and safety control for a variety of hematomas and solid tumors.
    note: There are deletions in the original text
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.